Leading manufacturer of medical devices and pharmaceutical products and services
B. Braun is one of the world's leading providers and manufacturers of healthcare solutions today. Every service that B. Braun provides incorporates the entirety of our knowledge and skills, the company's deep understanding of users' needs, and extensive expertise since 1839. With its constantly growing portfolio of effective medical care solutions, B. Braun makes a substantial contribution towards protecting and improving people's health. In total, the B. Braun product range comprises 5,000 different products, 95 percent of which are manufactured by the company. By offering supplementary services and consulting, B. Braun is a system supplier that develops the best solution for patients in close partnership with our customers, making a significant contribution to medical advancements.
Global portfolio
Therapies & Indications
- Cardio-Thoracic Surgery
- Continence Care & Urology
- Degenerative Spinal Disorders
- Diabetes Care
- Extracorporeal Blood Treatment
- General Open Surgery
- Infection Prevention
- Infusion Therapy
- Interventional Vascular Diagnostics and Therapy
- Laparoscopic Surgery
- Neurosurgery
- Nutrition Therapy
- Orthopaedic Joint Replacement
- Pain Therapy
- Ostomy Care
- Wound Management
Organization and management
The company’s operations are organized into four divisions - Hospital Care, Aesculap, Out Patient Market, and B. Braun Avitum.
Business development
Using treatment and service concepts that create value for our clients, as well as innovative products, we continue to develop our business model to meet this price and competitive pressure. Additionally, steps to reduce costs and increase internal efficiency were taken in previous years that produced results during the fiscal year. This active and strategic approach resulted in improved profitability in 2016, despite harsher market conditions. Overall, we are satisfied with performance for the fiscal year. The B. Braun Group is in good, stable financial condition. At the present time, we are not aware of any factors that could significantly impact the Group’s position.
| 2015 | 2016 | Change in % |
Sales | 6,129.8 | 6,471.0 | + 5.6 |
EBITDA | 878.1 | 975.0 | + 11.0 |
| Operating Profit (in € million) | 482.9 | 582.2 | + 20.6 |
Employees | 55,719 | 58,037 | + 4.2 |
The core themes of our Strategy 2020 are system partnership, collaboration and profitability. They are pursued in all divisions and regions and supported by central services and staff departments. The goal is to grow together in order to ensure that our company will be able to operate independently in the current strategic period. This will allow us in the future to continue making a contribution to protecting and improving the health of people all over the world.